Pozen (Nasdaq: POZN) lost $8.6 million, or 29 cents per share, in the third quarter, the pharmaceutical firm reported Thursday before the markets opened.

The company did earn $4.3 million in royalties from the same of the pain reliever Treximet and $400,000 in royalties for Vimovo.

Treximet revenues increased from $1.2 million in the same quarter last year.

A year ago, Pozen reported $14.3 million in revenues based primarily on milestone payments from drug development partners.

Expenses in the third quarter climbed to $13 million from $7.7 million a year ago due to new drug development and patent litigation, the company said.

For the full earnings report,

Get the latest news alerts: at Twitter.